			Phase 1	Phase 2	Phase 3

Neurology

Drug	Indication	Mechanism	Phase 1	Phase 2	Phase 3
valbenazine*	Sprinkle Formulation	VMAT2 Inhibitor	██	██	██
valbenazine*	Dyskinetic Cerebral Palsy	VMAT2 Inhibitor	██	██	█
NBI-827104§	Rare Pediatric Epilepsy: EE-CSWS	Ca_v 3.1, 3.2, 3.3	██	█	
NBI-921352##	Rare Pediatric Epilepsy: SCN8A-DEE	Na_v1.6	██	█	
NBI-1076986‖	Movement Disorders	M4 Antagonist	█		

Neuroendocrinology

Drug	Indication	Mechanism	Phase 1	Phase 2	Phase 3
crinecerfont†	Congenital Adrenal Hyperplasia in Adults	CRF_1	██	██	█
crinecerfont†	Congenital Adrenal Hyperplasia in Children & Adolescents	CRF_1	██	██	█
modified-release hydrocortisone	Adrenal Insufficiency	GC Receptor	██	█	
modified-release hydrocortisone	Congenital Adrenal Hyperplasia	GC Receptor	██	█	

Neuropsychiatry

Drug	Indication	Mechanism	Phase 1	Phase 2	Phase 3
valbenazine*	Adjunctive Treatment of Schizophrenia	VMAT2 Inhibitor	██	██	█
NBI-1065845¶	Inadequate Response to Treatment in Major Depressive Disorder	AMPA	██	█	
luvadaxistat¶	Cognitive Impairment Associated with Schizophrenia	DAAO	██	█	
NBI-1117568††	Schizophrenia	M4 Agonist	██	█	
NBI-1070770¶,‡‡	Major Depressive Disorder	NMDA NR2B NAM	██	█	
NBI-1117570††	CNS Indications	M1/M4 Agonist	█		
NBI-1117569††	CNS Indications	M4 Preferring Agonist	█		
NBI-1117567††,**,‖	CNS Indications	M1 Preferring Agonist	█		
NBI-1065890‖	CNS Indications	VMAT2 Inhibitor	█		

EE-CSWS = Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep.
SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome.
Neurocrine Biosciences has global rights, unless otherwise noted.
Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.
§ Licensed from Idorsia Ltd.
Licensed from Xenon Pharmaceuticals, Inc.
† Licensed from Sanofi.

¶ Licensed from Takeda Pharmaceutical Company Limited.
†† Licensed from Sosei Heptares.
** Sosei Heptares has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

‖ Phase 1 Initiating.
‡‡ Phase 2 Initiating.